

CLAIMS

1. An antibody reacting specifically reacting with a partial peptide in the C-terminal region of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 8, or a derivative of said polypeptide.
2. The antibody according to claim 1, which specifically reacts with a partial peptide in the C-terminal region of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6, or a derivative of said polypeptide.
3. The antibody according to claim 1, which specifically reacts with a peptide having the amino acid sequence represented by SEQ ID NO: 9.
4. The antibody according to claim 1, wherein the partial peptide in the C-terminal region is a peptide having (i) the 5-10 amino acid sequence in SEQ ID NO: 1, (ii) the 6-11 amino acid sequence in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 6, (iii) the 8-13 amino acid sequence in SEQ ID NO: 5, (iv) the 2-7 amino acid sequence in SEQ ID NO: 7, or (v) the 8-13 amino acid sequence in SEQ ID NO: 8.
5. The antibody according to claim 1, which is a monoclonal antibody.
6. The antibody according to claim 1, which is labeled.
7. The antibody according to claim 1, which is a neutralizing antibody.
8. The antibody according to claim 7, which neutralizes the activity of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8, or a derivative thereof.
9. The antibody according to claim 7, which neutralizes the activity of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6.
10. The antibody according to claim 5, which is shown by AUII5-6-10a capable of being produced from a hybridoma cell shown by AUII5-6-10 (FERM BP-8221).
11. The antibody according to claim 5, which is shown by AUII103-5-41a capable of being produced from a hybridoma cell shown by AUII103-5-41(FERM BP-8220).
- 35 12. A hybridoma cell capable of producing the antibody according to claim 5.

13. The hybridoma cell according to claim 12, which is shown by AUII103-5-41 (FERM BP-8220).

14. The hybridoma cell according to claim 12, which is shown by AUII5-6-10 (FERM BP-8221).

5 15. A method of producing the antibody according to claim 5, which comprises culturing the hybridoma cell according to claim 12 in vivo or in vitro and collecting the antibody according to claim 5 from the body fluid or its culture.

16. A pharmaceutical comprising the antibody according to claim 1.

10 17. The pharmaceutical according to claim 16, which is a preventive/therapeutic agent for central nerve diseases, mental disorders, circulatory diseases, heart diseases, renal diseases or urinary tract disorders.

18. A diagnostic agent comprising the antibody according to claim 1.

15 19. The diagnostic agent according to claim 18, which is a diagnostic agent for central nerve diseases, mental disorders, circulatory diseases, heart diseases, renal diseases or urinary tract disorders.

20 20. A method of quantifying a polypeptide having the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 8, or a derivative thereof, which comprises using the antibody according to claim 1.

21. A method of quantifying a polypeptide having the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 8, or a derivative thereof, in a test fluid, which comprises competitively reacting the antibody according to claim 1, a test fluid and a labeled form of polypeptide having the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8, or a derivative of said polypeptide, and determining a ratio of the labeled polypeptide having the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8, or a derivative thereof, 30 bound to the antibody.

22. A method for diagnosis of a disease associated with a polypeptide having the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8, or a derivative thereof, which comprises using the antibody according to claim 1.

35 23. A method of preventing/treating central nerve diseases, mental disorders, circulatory diseases, heart diseases, renal diseases or urinary tract disorders, which

comprises administering an effective dose of the antibody according to claim 1 to a mammal.

24. Use of the antibody according to claim 1 for manufacturing a preventive/therapeutic agent for central nerve diseases, mental disorders, circulatory diseases, heart diseases, renal diseases or urinary tract disorders.